Olanzapine for nausea and vomiting.
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Nausea and vomiting are often encountered in palliative care patients. Multiple medications are available to provide relief. However, several drug combinations are usually used to treat emesis. Current research has identified several receptors that trigger nausea and vomiting, hence the difficulty of using only 1 medication to provide relief. Olanzapine is a drug approved for treatment of schizophrenia and mania. It blocks multiple neurotransmitters dopaminergic, serotonergic, adrenergic (alpha(1)), histaminergic, and muscarinic receptors. Most of these receptors are also involved in causing emesis. Studies have shown that olanzapine could be used to treat nausea and vomiting with promising results.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Case reports, small retrospectively evaluated series, and a prospective pilot exploration support that olanzapine may be effective for the relief of nausea/vomiting, unrelated to chemotherapy, in patients with advanced cancer.[5][6][7][8][9][10][11]”
From Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial (2020) · cites this paper as [6]
Citations
Cites
Passik, S. D., Lundberg, J., Kirsh, K. L., Theobald, D., Donaghy, K., Holtsclaw, E., Cooper, M., & Dugan, W. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00391-3 · Cited by 154
Navari, R. M., Einhorn, L. H., Passik, S. D., Loehrer, P. J., Johnson, C. S., Mayer, M. L., McClean, J., Vinson, J., & Pletcher, W. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-004-0755-6 · Cited by 147 · cited 1×
“Nausea was very well controlled with no grade III or IV toxicities noted.(14) Aside from having control on nausea, olanzapine has also noted to have other benefits in palliative care patients such as increased appetite and weight gain.”
BackgroundChemotherapy-Induced Nausea and Vomiting
Lohr, L. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31816a0f07 · Cited by 144 · cited 6×
“However, with delayed CINV, they have similar efficacy than other medications.(7) Side effects include headache, diarrhea, and fatigue.”
BackgroundMethodInfluentialOlanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.
Srivastava, M., Brito-Dellan, N., Davis, M. P., Leach, M., & Lagman, R. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00143-x · Cited by 106 · cited 3×
“Olanzapine has 5 times the affinity for 5HT2 receptors than D2 receptors, hence fewer EPS effects.(6) Srivastava et al reported 2 cases with advanced cancer who had nausea refractory to standard antiemetics.”
BackgroundKAST, R. E., & FOLEY, K. F. (2007) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2006.00760.x · Cited by 104 · cited 1×
“Aside from having control on nausea, olanzapine has also noted to have other benefits in palliative care patients such as increased appetite and weight gain.(6,15) Other observations show that olanzapine can augment antidepressants in refractory melancholic depression.”
BackgroundStephenson, J., & Davies, A. N. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-005-0897-1 · Cited by 104 · cited 1×
“Nausea, especially, when accompanied by emesis can also result in serious complications such as aspiration, dehydration, malnutrition, and electrolyte imbalance.(2) Treatment usually entails pharmacologic agents and there are several available in the market.”
BackgroundPassik, S. D., Navari, R. M., Jung, S.-H., Nagy, C., Vinson, J., Kirsh, K. L., & Loehrer, P. (2004) · Cancer Investigation · doi:10.1081/cnv-200029066 · Cited by 102 · cited 1×
“In all, 3 patients had dose-limiting grade III toxicity secondary to depressed level of consciousness.(13) A phase II trial was completed in 2005, which was on olanzapine in the prevention of CINV.”
BackgroundPractical selection of antiemetics.
Flake, Z. A., Scalley, R. D., & Bailey, A. G. (2004) · PubMed · Cited by 101
Treatment of nausea and vomiting in advanced cancer
Davis, M. P., & Walsh, D. (2000) · Supportive Care in Cancer · doi:10.1007/s005200000151 · Cited by 99
Comparative activity of antiemetic drugs
Jordan, K., Schmoll, H., & Aapro, M. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.08.003 · Cited by 95 · cited 4×
“Side effects also include mild sedation, dystonic reactions, akathisia, and diarrhea.(11)”
BackgroundInfluentialPathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari, R. M. (2003) · PubMed · Cited by 89
Olanzapine for intractable nausea in palliative care patients.
Jackson, W. C., & Tavernier, L. (2003) · Journal of Palliative Medicine · doi:10.1089/109662103764978506 · Cited by 78 · cited 3×
“Most common side effect was sedation but this was better tolerated with careful dose titration over a period of 7 to 10 days.(4) In 2004, a phase I trial of olanzapine for preventing delayed emesis in patients with cancer was done by Passik et al.”
BackgroundInfluentialPassik, S. D., Kirsh, K. L., Theobald, D. E., Dickerson, P., Trowbridge, R., Gray, D., Beaver, M., Comparet, J., & Brown, J. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00078-2 · Cited by 56 · cited 1×
“However, to be able to provide relief, it usually requires multiple dosing and use of combination drugs that may have side effects or cause significant drug-drug interactions.(3) The introduction of the serotonin antagonist group has proven to be of benefit to these patients with nausea especially those associated wit…”
BackgroundEmerging drugs for chemotherapy-induced emesis
Navari, R. M., & Province, P. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.1.137 · Cited by 31 · cited 1×
“These signals are then collected in the vomiting center in the brain that processes these information and coordinates the mechanism of nausea and vomiting.(8) The CTZ is located in the area postrema of the fourth ventricle and has receptors for dopamine (D2), serotonin (5HT3), acetylcholine (ACHr), and opioids (MU2) t…”
BackgroundO'Brien, C. (2008) · PubMed · Cited by 13
Research works printed but not linked: 4
- Navari R., 2003, J Support Oncol, 1, 89
- O’Brien C., 2008, Can Fam Physician, 54, 861
- Flake ZA, 2004, Am Fam Physician, 69, 1169
- 2003, J Support Oncol, 1, 64
Cited by
Olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
Navari, R. M., Qin, R., Ruddy, K. J., Liu, H., Powell, S. F., Bajaj, M., Dietrich, L., Biggs, D., Lafky, J. M., & Loprinzi, C. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515725 · Cited by 452
Belvederi Murri, M., Guaglianone, A., Bugliani, M., Calcagno, P., Respino, M., Serafini, G., Innamorati, M., Pompili, M., & Amore, M. (2015) · Drugs in R&D · doi:10.1007/s40268-014-0078-0 · Cited by 174
“Nausea was rare, consistent with established olanzapine antiemetic properties [32], except when it was administered together with sertraline [33] or valproate [34].”
ResultGrassi, L., Caruso, R., Hammelef, K., Nanni, M. G., & Riba, M. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.842542 · Cited by 101
“Apart from the use of both phenothiazines and haloperidol, more recently atypical APs, especially olanzapine, have been demonstrated their effi cacy and safety (Ang et al., 2010; Licup, 2010).”
BackgroundNavari, R. M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.08.048 · Cited by 88
Pirri, C., Bayliss, E., Trotter, J., Olver, I., Katris, P., Drummond, P. D., & Bennett, R. M. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1574-9 · Cited by 92
Metadata
- Authors
- Licup, N., & Baumrucker, S.
- Affiliations
- East Tennessee State University (US)
- Corresponding author
- Licup, Nerissa
- ORCID
- Baumrucker, Steven
- Venue
- American Journal of Hospice and Palliative Medicine®
- Publisher
- SAGE Publications
- Published
- 2010-05-27
- Volume
- 27
- Issue
- 6
- Pages
- 432-434
- ISSN
- 1049-9091 (ISSN-L)
- 1938-2715
- OpenAlex
- W2171202006
- Cited by
- 23
- References
- 15
- Citations by year
- 2023: 1 · 2022: 2 · 2020: 6 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 2
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- American Journal of Hospice and Palliative Medicine® (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- olanzapine, nausea, vomiting, palliative care, antiemetics, dopamine receptors, serotonin receptors, muscarinic receptors, histamine receptors, adrenergic receptors, receptor antagonism
- MeSH terms
- Olanzapine, Antiemetics, Antineoplastic Agents, Benzodiazepines, Dose-Response Relationship, Drug, Humans, Nausea, Neoplasms, Quality of Life, Vomiting, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.